Mary-Claire King, a groundbreaking innovator in genetics, received The National Academy of Sciences' most prestigious metal.
Patient advocacy group Patients for Affordable Drugs (P4AD) yesterday filed its fourth amicus brief defending the Biden ...
Highlights,Bristol-Myers Squibb has seen adjustments in institutional holdings, reflecting shifts in market ...
Viatris forecast annual revenue and profit below Wall Street estimates on Thursday, mainly due to a worse-than-feared hit to sales from import restrictions on the drugmaker's manufacturing plant in ...
A year after the FDA rejected its marketing application for CD20xCD3 bispecific antibody odronextamab to treat two common ...
Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics ...
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) saw some unusual options trading on Tuesday. Traders acquired 46,473 call options on the company. This represents an increase of approximately 61% ...
Bristol-Myers Squibb saw an unexpected spike in options trading, with call options increasing by 61% compared to the average.
In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung cancer (NSCLC). The safety profile of the novel antibody-drug conjugate was ...
Shares of Bristol Myers Squibb Co. BMY slid 1.43% to $57.38 Wednesday, on what proved to be an all-around mixed trading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results